艾曲泊帕用于儿童免疫性血小板减少症
艾曲泊帕是目前美国食品药品监督管理局唯一批准用于儿童慢性免疫性血小板减少症(ITP)的血小板生成素受体激动剂。两项多中心、双盲、安慰剂对照临床试验(PETIT和PETIT2)显示,该口服每日一次疗法在升高血小板计数、减少出血和减少联合ITP治疗需求方面有效,不良反应相对较少。儿童长期安全性数据有限,成人研究未显示血栓形成、骨髓纤维化或白内障形成的临床显著发生率增加。
要点
- 艾曲泊帕是唯一获美国食品药品监督管理局批准用于儿童慢性ITP的血小板生成素受体激动剂。
- PETIT和PETIT2两项多中心双盲安慰剂对照试验证实其升高血小板、减少出血及减少联合治疗需求有效。
- 常见药物相关不良反应包括头痛、恶心和肝胆实验室异常;儿童长期安全性数据有限。
核心结论
- 艾曲泊帕在儿童慢性ITP中显示出良好的疗效和不良反应特征,但儿童长期安全性数据有限。
研究设计与样本
- 本文为综述,总结了两项多中心、双盲、安慰剂对照临床试验(PETIT和PETIT2)的结果。
主要发现
- PETIT和PETIT2试验证明艾曲泊帕能升高血小板计数、减少出血并减少联合ITP治疗需求,不良反应相对较少。
- 最常见药物相关不良反应包括头痛、恶心和肝胆实验室异常。
- 成人研究未显示血栓形成、骨髓纤维化或白内障形成的临床显著发生率增加;儿童长期安全性数据有限。
临床怎么用
- 艾曲泊帕已获批准用于治疗难治性重型再生障碍性贫血(AA),并可能在ITP、重型AA及其他伴血小板减少的疾病中扩大使用。
局限性
- 儿童长期安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Eltrombopag is currently the only US Food and Drug Administration-approved thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia (ITP) in children. This oral, once-per-day therapy has shown favorable efficacy and adverse effect profiles in children. Two multicenter, double-blind, placebo controlled clinical trials (PETIT [Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP)] and PETIT2 [Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body]) demonstrated efficacy in raising platelet counts, reducing bleeding, and reducing the need for concomitant ITP therapies with relatively few adverse effects. The most commonly reported drug-related adverse effects include headache, nausea, and hepatobiliary laboratory abnormalities. Long-term safety data in children are limited, and studies in adults have not revealed a clinically significant increased incidence of thrombosis, marrow fibrosis, or cataract formation. Eltrombopag has also been approved for treating refractory severe aplastic anemia (AA) and has potential for expanded use in ITP and severe AA as well as in other conditions associated with thrombocytopenia.
引用
- Kim TO, Despotovic J, Lambert MP, et al. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018. PMID: 29487060. doi:10.1182/bloodadvances.2017010660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。